证券代码：300529 证券简称：健帆生物 公告编号：2025-082 债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 关于预计触发转股价格向下修正条件的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、证券代码：300529 证券简称：健帆生物 2、债券代码：123117 债券简称：健帆转债 3、转股价格：38.65 元/股 4、转股期限：2021 年 12 月 29 日至 2027 年 6 月 22 日 5、根据公司《健帆生物科技集团股份有限公司创业板向不特定对象发行可 转换公司债券募集说明书》（以下简称"《募集说明书》"）规定：在可转债存 续期间，当公司股票在任意连续三十个交易日中至少有十五个交易日的收盘价格 低于当期转股价格的 85%时，公司董事会有权提出转股价格向下修正方案并提交 公司股东大会表决。 （三）可转债转股期限 自 2025 年 11 月 4 日至 2025 年 11 月 17 日，公司股票已有十个交易日低于 当期转股价格的 85%。若触发转股价格修正条件，公司将按照《募集说明书》的 约定 ...

南财智讯11月14日电，健帆生物在投资者关系活动中表示，为履行社会责任并应对市场竞争，公司自 2025年9月起主动将KHA130血液灌流器价格调降至339元，各省挂网实施时间以当地平台为准。2025年 前三季度KHA130占公司收入比重为5.22%，目前该降价举措对公司整体毛利率未产生较大影响，后续 影响将视市场推广效果而定，相关情况将在定期报告中披露。 ...

债券代码：123117 债券简称：健帆转债 证券代码：300529 证券简称：健帆生物 健帆生物科技集团股份有限公司 投资者关系活动记录表 编号：2025-005 投 资 者 关 系 活动类别 □ 特定对象调研 □ 分析师会议 □ 媒体采访 □ 业绩说明会 □ 新闻发布会 □ 路演活动 √ 现场参观 □ 其他（线上会议） 参与人员 珠海上市公司协会、华泰证券及参加"走进上市公司活动"的 24 位投资者 时间 2025 年 11 月 13 日 10:00-12:00 地点 珠海健帆科技园 上 市 公 司 接 待人员姓名 董事会秘书：黄聪 投 资 者 关 系 活 动 主 要 内 容介绍 一、参观公司展厅、生产车间、研发中心 二、公司介绍 三、交流问答环节 问题 1：请公司分析三季度业绩及同比下降原因。 答：2025 年前三季度，公司实现营业收入 15.56 亿元，同比下降 29.13%；实 现归属于上市公司所有者的净利润（以下简称"净利润"）4.53 亿元，同比下降 42.75%；实现经营性现金流量净额为 5.73 亿元，超出当期净利润 1.20 亿元，公 司现金流保持在高质量水平。前三季度公司的毛利率为 79. ...

证券代码：300529 证券简称：健帆生物 公告编号：2025-081 债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 关于不向下修正健帆转债转股价格的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 2025 年 11 月 3 日，健帆生物科技集团股份有限公司（以下简称"公司"） 召开第五届董事会第三十五次会议审议通过了《关于不向下修正健帆转债转股价 格的议案》，董事会决定本次不向下修正"健帆转债"转股价格。下一触发转股 价格修正条件的期间自 2025 年 11 月 3 日后首个交易日起重新计算，若再次触发 "健帆转债"转股价格向下修正条款，届时公司将按照相关规定履行审议程序， 决定是否行使"健帆转债"转股价格的向下修正权利。具体公告如下： 一、可转换公司债券基本情况 根据《深圳证券交易所创业板股票上市规则》等相关规定和《健帆生物科技 集团股份有限公司创业板向不特定对象发行可转换公司债券募集说明书》（以下 1 简称"《募集说明书》"）的有关约定，本次可转换公司债券转股期限自发行结 束之日（2021 年 6 月 29 ...

健帆生物科技集团股份有限公司（以下简称"公司"）第五届董事会第三十 五次会议于 2025 年 11 月 3 日在公司会议室以现场会议及通讯表决的方式召开， 本次会议应出席董事 9 人，实际出席董事 9 人，符合《公司法》和《公司章程》 的有关规定。本次会议通知提前以电子邮件及电话通知等方式向全体董事送达。 公司董事长董凡先生召集和主持了本次会议，公司部分监事和高级管理人员列席 了会议。本次董事会的召开符合《公司法》和《公司章程》的有关规定。 二、董事会会议审议情况 经与会董事认真讨论，审议并表决通过了以下议案： 健帆生物科技集团股份有限公司 第五届董事会第三十五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 证券代码：300529 证券简称：健帆生物 公告编号：2025-080 债券代码：123117 债券简称：健帆转债 1、审议通过了《关于不向下修正健帆转债转股价格的议案》 特此公告。 健帆生物科技集团股份有限公司董事会 2025 年 11 月 3 日 表决情况：7 票同意，0 票反对，0 票弃权，2 票回避。本议案表 ...

Core Viewpoint - The company experienced a significant decline in revenue and net profit in the first three quarters of 2025, attributed to inventory management and price adjustments, but maintains a positive long-term growth outlook due to increasing market penetration and product promotion efforts [1][2][3]. Financial Performance - Revenue for 1-3Q25 was 1.556 billion yuan, down 29.1% year-on-year, with a net profit of 453 million yuan, down 42.7% year-on-year [1]. - In 3Q25, revenue was 422 million yuan, a decrease of 39.8% year-on-year, and net profit was 63.51 million yuan, down 73.4% year-on-year [1]. Cost Structure and Efficiency - The gross margin for 1-3Q25 was 79.6%, a decrease of 1.7 percentage points year-on-year, likely due to changes in product sales structure [2]. - The sales, management, and R&D expense ratios were 24.6%, 7.4%, and 9.4%, respectively, with year-on-year increases of 1.4, 1.5, and 1.5 percentage points, reflecting a focus on long-term development despite short-term revenue declines [2]. Product Development and Market Position - The company remains optimistic about the long-term development of its core products, particularly blood purification devices, despite a decline in revenue due to various factors [3]. - As of 1H25, the company had over 6,000 and 2,000 hospital covers for its kidney and liver products, respectively, indicating strong market presence [3]. - Clinical recognition of the company's products is expected to improve with new guidelines and consensus from industry experts [3]. Business Expansion and New Opportunities - The company is actively expanding into new fields, including critical care and blood purification equipment, with over 1,800 and 2,000 hospitals covered by its respective products as of 1H25 [4]. - The company has also expanded its international presence, with products available in over 98 countries and regions, and received CE certification for its Future F20 blood purification device [4]. Profit Forecast and Valuation - The company expects net profits of 551 million, 607 million, and 668 million yuan for 2025-2027, with downward adjustments of 34%, 36%, and 38% compared to previous estimates [5]. - The company is considered a leader in the domestic blood purification industry, with a target price of 25.09 yuan based on a 33x PE valuation for 2026 [5].

Core Viewpoint - The company reported a significant decline in both revenue and net profit for the first three quarters of 2025, attributed to reduced industry demand and intensified market competition [1][2]. Financial Performance - The company achieved a revenue of 1.556 billion yuan, representing a year-on-year decrease of 29.13% [1]. - The net profit attributable to shareholders was 453 million yuan, down 42.75% year-on-year [1]. - The gross profit margin decreased by 1.72% due to a larger decline in production compared to revenue [1]. Operational Challenges - The decline in revenue was primarily due to reduced industry demand and increased market competition [1]. - The decrease in production led to a cost reduction that was lower than the revenue decline, impacting profitability [1]. - Ongoing investments in operations and business expansion resulted in a decline in period expenses that was less than the revenue decline, further exacerbating the net profit drop [1]. Market Reaction - Following the earnings report, the company's stock price opened lower and fell by over 5% at one point [2].

Core Viewpoint - The company reported a significant decline in both revenue and net profit for the first three quarters of 2025 compared to the previous year [1] Financial Performance - The company's operating revenue for the first three quarters was 1.556 billion yuan, representing a year-on-year decrease of 29.13% [1] - The net profit attributable to shareholders of the listed company was 453 million yuan, down 42.75% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 438 million yuan, reflecting a year-on-year decrease of 41.87% [1] - The basic earnings per share were 0.59 yuan [1]

Revenue and Profitability - Revenue for Q3 2025 was CNY 421,605,411.16, a decrease of 39.78% year-over-year, and year-to-date revenue was CNY 1,556,021,993.54, down 29.13% compared to the same period last year[4] - Net profit attributable to shareholders for Q3 2025 was CNY 63,507,610.17, a decline of 73.44% year-over-year, with year-to-date net profit at CNY 453,230,155.40, down 42.75%[4] - Basic earnings per share for Q3 2025 was CNY 0.083, a decrease of 72.33% compared to the same period last year, while diluted earnings per share was CNY 0.080, down 72.41%[4] - Total operating revenue for the current period is ¥1,556,021,993.54, a decrease of 29.1% compared to ¥2,195,690,243.92 in the previous period[25] - Net profit for the current period is ¥451,858,349.46, representing a decline of 42.7% from ¥788,826,841.30 in the previous period[26] - Basic earnings per share decreased to ¥0.59 from ¥0.99, a drop of 40.4%[26] Assets and Liabilities - Total assets as of September 30, 2025, were CNY 5,536,100,604.25, an increase of 2.84% from the end of the previous year[4] - The total current assets increased to ¥2,915,854,287.40 from ¥2,783,662,467.05, representing a growth of approximately 4.75%[22] - The total liabilities increased slightly from ¥2,048,784,541.14 to ¥2,107,445,959.36, reflecting a growth of about 2.00%[24] - The total equity attributable to shareholders rose from ¥3,333,906,225.54 to ¥3,429,268,141.05, an increase of approximately 2.87%[24] - The company's short-term borrowings decreased from ¥77,505,234.56 to ¥58,422,405.98, a reduction of about 24.65%[24] - The non-current liabilities increased from ¥1,281,991,218.31 to ¥1,422,240,153.75, representing a growth of about 10.95%[24] Cash Flow - Cash flow from operating activities year-to-date was CNY 573,240,155.17, a decrease of 34.23% compared to the same period last year[4] - Net cash flow from operating activities is ¥573,240,155.17, down 34.2% from ¥871,604,805.56 in the previous period[27] - Cash received from other operating activities increased by 69.88% to ¥96,557,078.25, mainly due to an increase in government subsidies related to assets[14] - Cash paid for other operating activities decreased by 34.12% to ¥265,858,918.17, attributed to cost control measures[14] - Cash received from investment income dropped by 64.20% to ¥8,757,199.60, mainly due to a decrease in maturing financial products[14] - Cash received from financing activities surged by 799.93% to ¥449,965,192.89, primarily due to the redemption of financial products related to financing activities[14] - Cash paid for debt repayment decreased by 91.18% to ¥32,120,327.44, reflecting a reduction in bank loan repayments[14] Financial Performance and Changes - The company reported a significant increase in trading financial assets, which rose by 241.90% to CNY 2,027,709,429.35 due to the purchase of wealth management products[8] - The company’s financial expenses increased by 33.65% to CNY 30,737,763.62, primarily due to adjustments in the funding structure and a decrease in deposit interest income[12] - The company experienced a 63.61% decline in other income, totaling CNY 18,950,231.78, mainly due to reduced government subsidies and VAT refunds[12] - The company reported a significant increase in fair value changes, with a gain of CNY 30,921,869.97, reflecting a 9137.44% increase due to changes in the fair value of held financial products[12] - Tax refunds received decreased by 33.63% to ¥946,942.18 compared to the previous year, primarily due to a reduction in VAT refunds[14] Market and Growth Opportunities - The number of hemodialysis patients in China is expected to grow by 12% year-on-year, reaching approximately 1.027 million by the end of 2024[15] - The introduction of new medical service pricing guidelines in June 2025 will include independent pricing for "hemodialysis perfusion" and "plasma adsorption," indicating a policy-driven growth opportunity[15] - The company is actively expanding into international markets and increasing new product development in metabolic cardiovascular diseases and related health management[16] Shareholder Information - The total number of common shareholders at the end of the reporting period was 51,243[18] Accounting and Audit - The company has not undergone an audit for the third quarter financial report[29] - The company plans to implement new accounting standards starting from 2025[29]

证券代码：300529 证券简称：健帆生物 公告编号：2025-078 债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 关于预计触发转股价格向下修正条件的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、证券代码：300529 证券简称：健帆生物 2、债券代码：123117 债券简称：健帆转债 3、转股价格：38.65 元/股 4、转股期限：2021 年 12 月 29 日至 2027 年 6 月 22 日 5、根据公司《健帆生物科技集团股份有限公司创业板向不特定对象发行可 转换公司债券募集说明书》（以下简称"《募集说明书》"）规定：在可转债存 续期间，当公司股票在任意连续三十个交易日中至少有十五个交易日的收盘价格 低于当期转股价格的 85%时，公司董事会有权提出转股价格向下修正方案并提交 公司股东大会表决。 自 2025 年 10 月 14 日至 2025 年 10 月 27 日，公司股票已有十个交易日低于 当期转股价格的 85%。若触发转股价格修正条件，公司将按照《募集说明书》的 约定及时履行后续审议程序 ...